Phototherapy News and Research

RSS

New findings reveal complexity of women's feelings about images of ageing

From the mundane to the magnificent, researchers find when women explore their feelings about being or becoming 'older women' their responses can be both challenging and humorous.

22 Mar 2011

Transcranial LED-based light therapy improves cognitive function in traumatic brain injury patients

At-home, daily application of light therapy via light-emitting diodes (LEDs) placed on the forehead and scalp led to improvements in cognitive function and post-traumatic stress disorder in patients with a traumatic brain injury (TBI), according to a groundbreaking study published in Photomedicine and Laser Surgery, a peer-reviewed journal published by Mary Ann Liebert, Inc.

18 Mar 2011

Bioengineers and physician-scientists zap tumors with light-activated nanoparticles

Rice University bioengineers and physician-scientists at Baylor College of Medicine and Texas Children's Hospital have successfully destroyed tumors of human brain cancer cells in the first animal tests of a minimally invasive treatment that zaps glioma tumors with heat. The tests involved nanoshells, light-activated nanoparticles that are designed to destroy tumors with heat and avoid the unwanted side effects of drug and radiation therapies.

2 Feb 2011

Natus announces acquisition of Medix

Natus Medical Incorporated today announced that it has acquired Medix, a leader in the development, manufacturing, and sales of devices for newborn care in Latin America. Medix, based in Argentina, manufactures incubators for use in hospital nurseries and neonatal intensive care units, transport incubators for use in ambulances and other emergency vehicles, infant warmers, and LED based phototherapy devices.

13 Oct 2010

Natus Medical second-quarter revenue increases to $52.7 million

Natus Medical Incorporated today announced financial results for the three and six months ended June 30, 2010.

29 Jul 2010

Twelve residents receive one-year fellowship grant to study medical dermatology

Twelve dermatology residents from leading medical schools around the country each received a $40,000, one-year fellowship grant to study medical dermatology. The fellowships, awarded by the National Psoriasis Foundation, provide support to eligible institutions to develop and enhance opportunities for physicians training for careers in medical dermatology.

1 Jul 2010

One in three people with psoriasis do not receive proper treatment due to health insurance issues: Survey

Results from a new survey reveal that one in three people with psoriasis do not receive proper treatment for their disease due to health insurance issues—and many won't be helped by the new health care reform law.

17 Jun 2010

Can-Fite BioPharma opens CF101 IND for psoriasis with US FDA

Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened Investigational New Drug application (IND) with the United States Food and Drug Administration (US FDA). The IND is for Can-Fite's lead compound, CF101, for the treatment of patients with psoriasis. This is the third US IND for CF101, and the fourth for Can-Fite.

8 Jun 2010

Psoriasis therapy costs outpace inflation

Findings from a cost model suggest that expenses for systemic psoriasis therapy appear to be increasing at a faster rate than inflation, and newer biologically derived treatments are more expensive than traditional systemic therapies, according to a report in the January issue of Archives of Dermatology, one of the JAMA/Archives journals.

19 Jan 2010

Lerner Medical Devices' Levia receives FDA clearance

Lerner Medical Devices, Inc. announced today that Levia®, a novel, in-home, ultraviolet B (UVB) phototherapy device, has received 510 (k) clearance from the U.S. Food and Drug Administration (FDA) for treatment of psoriasis and certain other skin conditions such as vitiligo.

6 Jan 2010

"Tan Tax" will hurt middle-class women and women-owned businesses

The proposed 10 percent federal tax on indoor tanning services, added to the latest U.S. Senate health care reform bill in a back-room deal over the weekend, will fall 40-50 percent short of delivering the revenue its proponents promised, according to the International Smart Tan Network (Smart Tan). The tax unfairly targets female consumers, who make up more than two-thirds of tanning clients, and would be detrimental to the thousands of women who own the majority of America's indoor tanning salons.

24 Dec 2009

Lerner Medical Devices selects QuantumMethod for branding and launching its Levia phototherapy device

QuantumMethod announced today that Lerner Medical Devices, Inc. has selected the firm as agency of record, tasked with branding and launching Levia®, the company's new Personal Targeted Phototherapy™ device for the self-treatment of psoriasis. Levia® enables their patients to target their small area and scalp psoriasis with therapeutic ultraviolet light via proprietary delivery systems designed for precise, fast and safe treatment.

11 Nov 2009

FDA approves Istodax for treatment of Cutaneous T-cell Lymphoma

The U.S. Food and Drug Administration has approved Istodax (romidepsin), an injectable medication, for treatment of patients with a rare form of cancer known as Cutaneous T-cell Lymphoma (CTCL).

10 Nov 2009

Bursting common myths about psoriasis

Psoriasis is a real disability that affects approximately one million Canadians. A recent Canadian survey found that the causes and effects of this chronic, recurrent skin disorder are often misunderstood - and the result of these misperceptions can leave a lasting negative impact on those who suffer from this debilitating immune system disease.

5 Nov 2009

Keraderm raises $2.5 million from institutional investor

Keraderm Corp. announced the closing today of a $2.5 million dollar Series A investment by NewVa Capital Partners, LP. Currently starting clinical trials, the company's platform harnesses phototherapy technology to treat nail and skin infections. NewVa Capital Partners is a private equity and venture capital fund managed by Third Security, LLC and provides early stage investments in companies located or considering location in the NewVa region of southwest Virginia. This is Keraderm's first institutional investment round.

24 Oct 2009

New guidelines from American Academy of Dermatology for treatment of psoriasis with ultraviolet light therapy

Based on an extensive review of the highest quality scientific literature on psoriasis and the opinion of recognized psoriasis experts, the American Academy of Dermatology (Academy) has released new guidelines of care for the management and treatment of psoriasis with ultraviolet (UV) light therapy, also known as phototherapy. Recommendations for the use of the most common forms of UV light therapy, as stand-alone treatments or in conjunction with other therapies, were outlined, including patient considerations.

23 Oct 2009

Premier Plastic Surgery redesigns its website to provide more information of cosmetic surgery

Premier Plastic Surgery of Kansas City, serving residents of Kansas City and beyond for 22 years, has redesigned its extensive website to include a separate section on Cosmetic Surgery for Males, a new Skin Care Centre, and a Plastic Surgery Blog that features breaking news on emerging research, techniques and products.

19 Oct 2009

National Biological to market Quantel's 308 Excimer System in the U.S.

Quantel SA (Euronext: QUA), a leading manufacturer of solid state lasers, announced today that it has entered into a Distribution Agreement with National Biological, a leading researcher and developer of light-based systems for medical and cosmetic treatments, for Quantel's 308 Excimer System for monochromatic UVB treatment of psoriasis and vitiligo in the United States.

15 Oct 2009

Johnson & Johnson announces financial results for the third quarter of 2009

Johnson & Johnson today announced sales of $15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%. Domestic sales declined 8.1%, while international sales declined 2.5%, reflecting operational growth of 2.4% and a negative currency impact of 4.9%.

13 Oct 2009

Can-Fite BioPharma commences preparatory work for a Phase III trial with CF101 to treat Psoriasis

Can-Fite BioPharma, a biotechnology company traded on the Tel Aviv Stock Exchange, an Israeli Biopharmaceutical company, announced today the initiation of preparatory work for a Phase III trial with CF101 in Psoriasis. This is based on the successful conclusion of a Phase II dose-response clinical study with CF101 to treat patients with moderate to severe Psoriasis; the study successfully met its primary objective of efficacy and safety

1 Oct 2009